Abstract
Current therapies for ischemic heart failure are not sufficient.
Regenerative therapy is a promising strategy that
has rapidly developed into a clinical phase. Although
the exact mechanism of action is not entirely understood,
clinical results show a statistically significant effect of
stem cells in ischemic heart diseases. At this moment
there is no consensus on the clinical relevance of stem
cell therapy. In this review we discuss the rationale for
stem cell therapy. We will focus on autologous bone
marrow cells in clinical setting. Finally, we will give an
overview of new developments that will optimize future
cell therapy.
Regenerative therapy is a promising strategy that
has rapidly developed into a clinical phase. Although
the exact mechanism of action is not entirely understood,
clinical results show a statistically significant effect of
stem cells in ischemic heart diseases. At this moment
there is no consensus on the clinical relevance of stem
cell therapy. In this review we discuss the rationale for
stem cell therapy. We will focus on autologous bone
marrow cells in clinical setting. Finally, we will give an
overview of new developments that will optimize future
cell therapy.
| Translated title of the contribution | Stem cell therapy for the damaged heart |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 95-100 |
| Journal | Nederlands Tijdschrift voor Hematologie |
| Volume | 13 |
| Issue number | 3 |
| Publication status | Published - Apr 2016 |
Keywords
- Ischemic cardiomyopathy
- ischemic heart disease
- myocardial infarction
- stem cell therapy
- ischemische cardiomyopathie
- ischemische hartziekte
- myocardinfarct
- stamceltherapie